跳至主導覽
跳至搜尋
跳過主要內容
臺北醫學大學 首頁
說明與常見問題
連結會在新分頁中打開
English
中文
在 臺北醫學大學 搜尋內容
首頁
專家檔案
研究單位
專案
研究成果
資料集
活動
查看斯高帕斯 (Scopus) 概要
許 永和
教授
,
腎臟內科
合聘教授
,
臨床醫學研究所
成員
,
臺北醫學大學泌尿腎臟研究中心
成員
,
臺北醫學大學生醫器材研究中心
主治醫師
,
臺北市立萬芳醫院
成員
,
臺北醫學大學人工智慧醫療研究中心
https://orcid.org/0000-0002-6090-3418
電子郵件
yhhsu
tmu.edu
tw
,
88347
w.tmu.edu
tw
h-index
3263
引文
32
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
1991 …
2025
每年研究成果
概覽
指紋
網路
專案
(22)
研究成果
(143)
資料集
(3)
類似的個人檔案
(12)
指紋
查看啟用 Yung-Ho Hsu 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Kidney Failure
100%
Hemodialysis
70%
Rat
46%
Gentamicin
27%
End Stage Renal Disease
26%
All Cause Mortality
23%
Arteriovenous Fistula
22%
Protein Kinase B
21%
Cardiovascular Disease
19%
Kidney Disease
18%
Prostacyclin
18%
Reactive Oxygen Metabolite
17%
Cohort Study
17%
Hypertension
16%
Acute Kidney Failure
15%
Dipeptidyl Carboxypeptidase Inhibitor
15%
Angiotensin Receptor Antagonist
15%
Nephrotoxicity
15%
Fibrosis
15%
Peroxisome Proliferator Activated Receptor
14%
Doxorubicin
14%
Inflammasome
14%
Parathyroid Hormone
14%
Fucoidan
14%
Therapeutic Effect
14%
Diabetes Mellitus
13%
Deterioration
13%
Cinacalcet
13%
Endothelin 1
11%
Replacement Therapy
11%
Adverse Outcome
10%
Antihypertensive Agent
10%
Inflammation
10%
Randomized Controlled Trial
9%
Monotherapy
9%
Cardiovascular Mortality
9%
Urotensin II
8%
Case-Control Study
8%
Nanoparticle
8%
Carbon Monoxide Poisoning
8%
Hypoxia Inducible Factor 1
8%
Fucoxanthin
8%
Sodium Ion
8%
Leptin
8%
Stevioside
8%
Cerebrovascular Accident
8%
Loop Diuretic Agent
8%
Tetramethylpyrazine
8%
Epidermal Growth Factor Receptor
8%
Peritoneal Fibrosis
8%
Medicine and Dentistry
Chronic Kidney Disease
51%
Hemodialysis
41%
Arteriovenous Fistula
22%
Nephropathy
20%
Cohort Analysis
19%
Cardiovascular Disease
18%
End Stage Renal Disease
18%
Internal Medicine
17%
Nephrology
14%
Peritoneal Dialysis
14%
Kidney Function
13%
Prevalence
10%
All Cause Mortality
9%
Deterioration
9%
4 Iodo 2,5 Dimethoxyamphetamine
8%
Metabolic Syndrome
8%
Adverse Outcome
8%
Division
8%
Meta-Analysis
8%
Randomized Controlled Trial
8%
Diabetes Mellitus
8%
Congestive Heart Failure
6%
Odds Ratio
6%
Proportional Hazards Model
6%
Cross Sectional Study
6%
Mortality Rate
6%
Angiotensin Receptor Antagonist
6%
ACE Inhibitor
6%
Cardiovascular Risk
5%
Diabetes
5%
Programmed Cell Death
5%
Protein Kinase B
5%
Maturation
5%
Logistic Regression Analysis
5%
Cardiology
5%
Acute Kidney Injury
5%
Observational Study
5%
Cardiovascular Mortality
5%
Catenin
5%
Systolic Blood Pressure
5%
Nursing and Health Professions
Chronic Kidney Failure
40%
Hemodialysis
36%
Cardiovascular Disease
16%
End Stage Renal Disease
13%
School Health Service
13%
Cross-Sectional Study
11%
Propensity Score
10%
Insulin Resistance
10%
Body Mass
9%
Education
9%
Adverse Outcome
8%
Deterioration
8%
Meta Analysis
8%
Muscle Mass
8%
Prevalence
8%
Cohort Analysis
7%
Kidney Disease
7%
All Cause Mortality
6%
Confidence Interval
6%
Treatment Outcome
5%
Acute Kidney Failure
5%
C Reactive Protein
5%
Hyperhomocysteinemia
5%
